Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -2.34%10 Debt-to-Equity is 0.16 as of Jan. 2026, which is 33% above its 10-year median of 0.12. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 58.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kestra Medical Technologies's Debt-to-Equity or its related term are showing as below:
KMTS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.28 Med: 0.12 Max: 12.94
Current: 0.16
During the past 4 years, the highest Debt-to-Equity Ratio of Kestra Medical Technologies was 12.94. The lowest was -2.28. And the median was 0.12.
KMTS's Debt-to-Equity is ranked better than 58.22% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs KMTS: 0.16
Kestra Medical Technologies (NAS:KMTS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kestra Medical Technologies Debt-to-Equity Related Terms
Kestra Medical Technologies Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KMTS vs ATRC, STAA, BLFS: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a Debt-to-Equity of 0.16 as of Jan. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kestra Medical Technologies and its competitors. This is 33% above median its historical median of 0.12. According to the industry distribution chart, Kestra Medical Technologies ranks #295 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 41.8%.
Is Kestra Medical Technologies' Debt-to-Equity too high?
Kestra Medical Technologies' current Debt-to-Equity of 0.16 is 33% above median its 10-year median of 0.12. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Kestra Medical Technologies' value of 0.16 is 28.9% below this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #295 out of 706 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Debt-to-Equity compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #295 out of 706 companies for Debt-to-Equity. This puts Kestra Medical Technologies in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Kestra Medical Technologies' value of 0.16 is 28.9% below this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.23, Kestra Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Debt-to-Equity of 0.16 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Debt-to-Equity is 0.16, which is 33% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Debt-to-Equity of 0.16. The current Debt-to-Equity is 0.16, which is 33% above median its 10-year median of 0.12 and 28.9% below the Medical Devices & Instruments industry median of 0.23. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Debt-to-Equity is 0.16 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
